Key points are not available for this paper at this time.
OBJECTIVES: We evaluated the efficacy, safety and impact on viral reservoir of rapid bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) initiation during primary HIV infection (PHI). METHODS: Multicenter, single-arm clinical trial in participants with PHI of 0.001). Intact and defective proviral DNA levels significantly decreased at 48-weeks. CONCLUSIONS: BIC/FTC/TAF showed rapid viral decay, high suppression rates, good tolerability, and reservoir decline in PHI, making it an appealing regimen in this setting.
Ambrosioni et al. (Sat,) studied this question.